Policy

Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close July 24, 2025

Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the final close of its sixth fund at $439 million.

Sanofi to acquire Vicebio, gaining rights to Queensland discovered technology July 23, 2025

Sanofi has agreed to acquire Vicebio, a privately held biotechnology company headquartered in London, which has rights to the Molecular Clamp Technology developed at the University of Queensland.

Nyrada advances Xolatryp towards Phase 2a trial in cardioprotection July 23, 2025

Nyrada (ASX:NYR) has announced its intention to progress its candidate Xolatryp into a Phase 2a clinical trial for the treatment of acute myocardial infarction.

OncoSil Medical completes recruitment in TRIPP-FFX clinical trial July 23, 2025

Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) has completed patient recruitment for the TRIPP-FFX clinical trial.

Amplia Therapeutics announces $25 million placement and launches share purchase plan July 23, 2025

Amplia Therapeutics (ASX:ATX) has successfully undertaken an institutional placement of $25 million in new, fully paid ordinary shares in the company at a price of $0.23 per share.

Percheron Therapeutics announces publication of new preclinical HMBD-002 data July 23, 2025

Percheron Therapeutics (ASX:PER) has shared new preclinical data for its investigational cancer drug, HMBD-002.

Radiopharm Theranostics announces new appointment to advisory board July 22, 2025

Dr Oliver Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies.

Study identifies potential world-first treatments to prevent a life-threatening infection July 22, 2025

A study co-led by WEHI and the Peter Doherty Institute for Infection and Immunity has found that existing HIV drugs can suppress transmission of the HTLV-1 virus in mice.

Osteopore secures clearance for jawbone trial at Princess Alexandra Hospital July 22, 2025

Australian regenerative medicine company Osteopore (ASX:OSX) has secured clearance from the Research Governance Office at Princess Alexandra Hospital in Brisbane for its clinical trial for jawbone regeneration.

Mesoblast updates investors on the successful US launch of cell medicine July 22, 2025

Australian allogeneic cellular medicines company Mesoblast (ASX:MSB) has reported gross revenue of US$13.2 million from the sales of Ryoncil following its launch at the end of March.

Atomo Diagnostics announces successful placement from Share Purchase Plan shortfall July 22, 2025

Australian-headquartered medical device company Atomo Diagnostics (ASX:AT1) has announced that it has placed the shortfall of $727,612.50 from the Share Purchase Plan with a range of sophisticated investors.

Brandon BioCatalyst welcomes the inclusion of its CUREator in new program July 16, 2025

Brandon BioCatalyst has welcomed the inclusion of its national biotechnology incubator, CUREator, in a new $100 million program funded by the Australian Government's Medical Research Future Fund.

Most Read

Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close

Sanofi to acquire Vicebio, gaining rights to Queensland discovered technology

Amplia Therapeutics announces $25 million placement and launches share purchase plan

OncoSil Medical completes recruitment in TRIPP-FFX clinical trial

Percheron Therapeutics announces publication of new preclinical HMBD-002 data

New Stories

Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close

Sanofi to acquire Vicebio, gaining rights to Queensland discovered technology

OncoSil Medical completes recruitment in TRIPP-FFX clinical trial

Nyrada advances Xolatryp towards Phase 2a trial in cardioprotection

Amplia Therapeutics announces $25 million placement and launches share purchase plan

Percheron Therapeutics announces publication of new preclinical HMBD-002 data

Radiopharm Theranostics announces new appointment to advisory board

Sign In

Most Read

Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close

Sanofi to acquire Vicebio, gaining rights to Queensland discovered technology

Amplia Therapeutics announces $25 million placement and launches share purchase plan

OncoSil Medical completes recruitment in TRIPP-FFX clinical trial

Percheron Therapeutics announces publication of new preclinical HMBD-002 data

Follow Us

New Stories

Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close

Sanofi to acquire Vicebio, gaining rights to Queensland discovered technology

OncoSil Medical completes recruitment in TRIPP-FFX clinical trial

Nyrada advances Xolatryp towards Phase 2a trial in cardioprotection

Amplia Therapeutics announces $25 million placement and launches share purchase plan

Percheron Therapeutics announces publication of new preclinical HMBD-002 data

Radiopharm Theranostics announces new appointment to advisory board